摘要
局部晚期鼻咽癌的治疗主要采用以放射治疗为主的综合治疗。随着放疗技术的进步尤其适形调强放疗(intensity-modulated radiation therapy,IMRT)的广泛应用,其局部和区域控制率得到明显提高,远处转移成为治疗失败的首要原因。为了降低局部晚期鼻咽癌患者远处转移的发生率,提高生存率,IMRT需与化疗、靶向治疗及免疫治疗等其他治疗手段相结合。如何将这些治疗方法更好结合是目前研究的热点。本文通过对IMRT时代局部晚期鼻咽癌的临床研究进行综述,探索其最佳综合治疗模式。
Radiotherapy is the primary treatment modality for locally advanced nasopharyngeal carcinoma(NPC).With the development of radiotherapy especially the wide applications of intensity-modulated radiation therapy(IMRT),local control rate of nasopharyngeal carcinoma has been improved,distant metastasis remains the major type of treatment failure.In order to control the rate of distant metastasis,and thus improve survival outcome of locally advanced NPC,IMRT should be combined with other treatment modalities such as chemotherapy,molecular targeting therapy and Immune therapy.It is a research hotspot recent years to determine a better combination of these therapeutic regimens.This article reviews the progress of the comprehensive treatment of locally advanced NPC in the IMRT era to explore the best comprehensive treatment modality.
引文
[1] Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012 [J].CA Cancer J Clin,2015,65(2):87-108.
[2] Mao YP,Xie FY,Liu LZ,et al.Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging [J].Int J Radiat Oncol Biol Phys,2009,73(5):1326-1334.
[3] Au KH,Ngan RKC,Ng AWY,et al.Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong:A report of 3328 patients (HKNPCSG 1301 study) [J].Oral Oncol,2018,77:16-21.
[4] Lee N,Harris J,Garden AS,et al.Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma:radiation therapy oncology group phase II trial 0225 [J].J Clin Oncol,2009,27(22):3684-3690.
[5] Sun X,Su S,Chen C,et al.Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma:an analysis of survival and treatment toxicities [J].Radiother Oncol,2014,110(3):398-403.
[6] Wong FC,Ng AW,Lee VH,et al.Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma [J].Int J Radiat Oncol Biol Phys,2010,76(1):138-145.
[7] Al-Sarraf M,LeBlanc M,Giri PG,et al.Chemoradiotherapy versus radiotherapy in patientswith advanced nasopharyngeal cancer:phase III randomized Intergroup study 0099 [J].J Clin Oncol,1998,16(4):1310-1317.
[8] Lin JC,Jan JS,Hsu CY,et al.Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma:positive effect on overall and progression-free survival [J].J Clin Oncol,2003,21(4):631-637.
[9] Zhang L,Zhao C,Peng PJ,et al.Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma:preliminary results [J].J Clin Oncol,2005,23(33):8461-8468.
[10] Peng G,Wang T,Yang KY,et al.A prospective,randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs.conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma [J].Radiother Oncol,2012,104(3):286-293.
[11] Hui EP,Ma BB,Leung SF,et al.Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma [J].J Clin Oncol,2009,27(2):242-249.
[12] Sun Y,Li WF,Chen NY,et al.Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma:a phase 3,multicentre,randomised controlled trial [J].Lancet Oncol,2016,17(11):1509-1520.
[13] Cao SM,Yang Q,Guo L,et al.Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma:A phase III multicentre randomised controlled trial [J].Eur J Cancer,2017,75:14-23.
[14] Chen YP,Tang LL,Yang Q,et al.Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma:Individual Patient Data Pooled Analysis of Four Randomized Trials [J].Clin Cancer Res,2018,24(8):1824-1833.
[15] Peng H,Tang LL,Chen BB,et al.Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma:A big-data intelligence platform-based analysis [J].Oral Oncol,2018,79:40-46.
[16] Lim AM,Corry J,Collins M,et al.A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma [J].Oral Oncol,2013,49(5):468-474.
[17] He X,Ou D,Ying H,et al.Experience with combination of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma [J].Eur Arch Otorhinolaryngol,2012,269(3):1027-1033.
[18] Kasibhatla M,Kirkpatrick JP,Brizel DM.How much radiation is the chemotherapy worth in advanced head and neck cancer?[J].Int J Radiat Oncol Biol Phys,2007,68(5):1491-1495.
[19] Yi J,Huang X,Gao L,et al.Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma [J].Radiat Oncol,2014,9:56.
[20] Ou X,Zhou X,Shi Q,et al.Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy:new insight into the value of total dose of cisplatin and radiation boost [J].Oncotarget,2015,6(35):38381-38397.
[21] Cao CN,Luo JW,Gao L,et al.Update report of T4 classification nasopharyngeal carcinoma after intensity-modulated radiotherapy:an analysis of survival and treatment toxicities [J].Oral Oncol,2015,51(2):190-194.
[22] Yao JJ,Yu XL,Zhang F,et al.Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma:a retrospective comparison of toxicity and prognosis [J].Chin J Cancer,2017,36(1):26.
[23] Liu YC,Wang WY,Twu CW,et al.Comparison Long-term Outcome of Definitive Radiotherapy plus Different Chemotherapy Schedules in Patients with Advanced Nasopharyngeal Carcinoma [J].Sci Rep,2018,8(1):470.
[24] Tang LQ,Chen DP,Guo L,et al.Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma:an open-label,non-inferiority,randomised phase 3 trial [J].Lancet Oncol,2018,19(4):461-473.
[25] Meng DF,Sun R,Peng LX,et al.A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy:a matched study [J].J Cancer,2018,9(1):92-99.
[26] Peng L,Xu C,Chen YP,et al.Optimizing the cumulative cisplatin dose during radiotherapy in nasopharyngeal carcinoma:Dose-effect analysis for a large cohort [J].Oral Oncol,2019,89:102-106.
[27] Chen L,Hu CS,Chen XZ,et al.Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma:a phase 3 multicentre randomised controlled trial [J].Lancet Oncol,2012,13(2):163-171.
[28] Chen L,Hu CS,Chen XZ,et al.Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma:Long-term results of a phase 3 multicentre randomised controlled trial [J].Eur J Cancer,2017,75:150-158.
[29] Chi KH,Chang YC,Guo WY,et al.A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients [J].Int J Radiat Oncol Biol Phys,2002,52(5):1238-1244.
[30] Kwong DL,Sham JS,Au GK,et al.Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma:a factorial study [J].J Clin Oncol,2004,22(13):2643-2653.
[31] Rossi A,Molinari R,Boracchi P,et al.Adjuvant chemotherapy with vincristine,cyclophosphamide,and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer:results of a 4-year multicenter randomized study [J].J Clin Oncol,1988,6(9):1401-1410.
[32] Lin JC,Liang WM,Jan JS,et al.Another way to estimate outcome of advanced nasopharyngeal carcinoma-is concurrent chemoradiotherapy adequate?[J].Int J Radiat Oncol Biol Phys,2004,60(1):156-164.
[33] Liu YC,Wang WY,Twu CW,et al.Prognostic impact of adjuvant chemotherapy in high-risk nasopharyngeal carcinoma patients [J].Oral Oncol,2017,64:15-21.
[34] Lin JC,Wang WY,Chen KY,et al.Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma [J].N Engl J Med,2004,350(24):2461-2470.
[35] Lin JC,Wang WY,Liang WM,et al.Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy [J].Int J Radiat Oncol Biol Phys,2007,68(5):1342-1348.
[36] Wang WY,Twu CW,Chen HH,et al.Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma [J].Clin Cancer Res,2010,16(3):1016-1024.
[37] Chan ATC,Woo JKS,King A,et al.Analysis of Plasma Epstein-Barr Virus DNA to Screen fo Nasopharyngeal Cancer[J].N Engl J Med,2017,377(6):513-522.
[38] Zhang P,Wu SK,Wang Y,et al.p53,MDM2,eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis:A retrospective study [J].Oncol Lett,2015,9(1):113-118.
[39] Huang JF,Zhang FZ,Zou QZ,et al.Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma:preliminary results from a phase II clinical trial [J].Oncotarget,2017,8(2):2457-2465.
[40] Kong L,Lin Q,Hu C,et al.Radiation Plus Concurrent Nimotuzumab Versus Cisplatin-Based Chemotherapy in Locally Advanced Nasopharyngeal Cancer:An Interim Analysis of a Phase 3 Randomized Clinical Trial[J].International Journal of Radiation Oncology Biology Physics,2015,93(3):S129-S129.
[41] Peng H,Tang LL,Liu X,et al.Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma:a big-data,intelligence platform-based analysis [J].BMC Cancer,2018,18(1):323.
[42] You R,Hua YJ,Liu YP,et al.Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma:Retrospective Analysis with a Large Cohort and Long Follow-up [J].Theranostics,2017,7(8):2314-2324.
[43] Bibault JE,Morelle M,Perrier L,et al.Toxicity and efficacy of cetuximab associated with several modalities of IMRT for locally advanced head and neck cancer [J].Cancer Radiother,2016,20(5):357-361.
[44] Zhang J,Fang W,Qin T,et al.Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma [J].Med Oncol,2015,32(3):86.
[45] Fang W,Yang Y,Ma Y,et al.Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma:results from two single-arm,phase 1 trials [J].Lancet Oncol,2018,19(10):1338-1350.
[46] Hsu C,Lee SH,Ejadi S,et al.Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma:Results of the KEYNOTE-028 Study [J].J Clin Oncol,2017,35(36):4050-4056.
[47] Ma BBY,Lim WT,Goh BC,et al.Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma:An International,Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742) [J].J Clin Oncol,2018,36(14):1412-1418.
